AtriCure, Inc. Hits New 52-Week Low at $27.31

AtriCure, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 27.31 on April 9, 2026. This marks a significant decline from its 52-week high of USD 43.18, reflecting the stock's volatility over the past year. Despite this downturn, AtriCure has shown a 1-year performance of 28.38%, outperforming the S&P 500, which recorded a performance of 25.06% during the same period. The company's market capitalization stands at USD 1,516 million, indicating its position within the small-cap segment of the market. Financial metrics reveal that AtriCure is currently loss-making, with a negative return on equity of -1.16% and a debt-to-equity ratio of -0.21. The stock does not offer a dividend yield, and its price-to-book ratio is 3.08. These figures provide insight into the company's financial health and market standing as it navigates through current market conditions.